• br Development of calibrators and controls for DiXaIs br

  2021-12-17

  

  Development of calibrators and controls for DiXaIs Method validation and comparison with reference technique (LC:MS) At this stage, anti-Factor Xa bioassays can be established for reliably measuring DiXaI concentrations in plasma, with the available appropriate drug specific calibrators and co

• br Acknowledgments R Dalmann has

  2021-12-17

  

  Acknowledgments R. Dalmann has obtained a “bourse Cifre” (grant 304/2011) from the ‘Association Nationale de la Recherche Technique’ and Bristol-Myers-Squibb. Introduction Endocannabinoids, their molecular targets (receptors), their synthetic and degrading enzymes and proteins that transport

• EZH mutations or amplifications have been found in a broad

  2021-12-17

  

  EZH2 mutations or amplifications have been found in a broad spectrum of human cancers including B cell lymphoma, ovarian cancer, breast cancer, melanoma, bladder cancer, gastric cancer, and other cancers (Kim and Roberts, 2016). Given the evidence of EZH2 as a cancer driver, numerous efforts have be

• br Hepatitis C virus HCV infection is a

  2021-12-17

  

  Hepatitis C virus (HCV) infection is a major cause of chronic liver disease that can lead to cirrhosis and hepatocellular carcinoma. It is estimated that nearly 200 million individuals worldwide are currently infected with HCV and it is the leading cause of liver transplants. The current standard

• The current research also analyzed

  2021-12-17

  

  The current research also analyzed the association of this polymorphism with HCV genotype 1-related hepatic steatosis by gender. Even though the allele and genotypes of this polymorphism an increased the risk of HCV-related hepatic steatosis, neither allele nor genotype frequency of this polymorphis

• To date very little is known about the GEFs that

  2021-12-17

  

  To date, very little is known about the GEFs that regulate RhoA during amoeboid migration. GEF-H1, a RhoA GEF, is activated response to microtubule destabilization and promotes amoeboid migration (Eitaki, Yamamori, Meike, Yasui, & Inanami, 2012). Interestingly, the majority of 66 8 depleted of anot

• Pharmacologic approaches of inhibiting GSNOR activity have r

  2021-12-17

  

  Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications

• br Introduction Nicotinic acid has been used clinically for

  2021-12-17

  

  Introduction Nicotinic IL-18, human recombinant protein has been used clinically for more than 50 years [1] since it has anti-atherogenic effects, including the ability to reduce triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C), and elevate high-density lipoprotein cholesterol (

• br Materials and methods br

  2021-12-17

  

  Materials and methods Results In order to address the role played by the catalytic and the anticodon-binding domains of E. coli GluRS in cognate and non-cognate aminoacylation, the two domains (NGluRS: 1–314; CGluRS: 318–471) of E. coli were expressed and purified (Fig. 1b). Prior to assessing

• Phylogenetic trees of receptors for peptides similar to gluc

  2021-12-17

  

  Phylogenetic trees of receptors for peptides similar to glucagon from diverse vertebrate species typically are similar to the tree presented in Fig. 3 (Sivarajah et al., 2001, Chow et al., 2004, Irwin and Wong, 2005, Cardoso et al., 2005, Cardoso et al., 2006, Ng et al., 2010, Park et al., 2013, Hwa

• Given the actions of GIP analogues administered

  2021-12-17

  

  Given the actions of GIP analogues administered as a single dose to ob/ob mice, studies were performed to assess their ability to act in vivo as antagonists of GIP-induced insulinotropic and antihyperglycaemic actions. (Ala3)GIP, (Phe3)GIP, (Tyr3)GIP and (Pro3)GIP all counteracted the glucose-loweri

• Some clinical reports have suggested that galanin has a role

  2021-12-17

  

  Some clinical reports have suggested that galanin has a role in the neurobiology of mood disorders [[6], [7], [8], [9], [10]]. In behavioral studies, contradictory results have been reported [11,12]. For example, systemic administration of non-selective galanin receptor agonists, such as galmic [13]

• In the light of the

  2021-12-16

  

  In the light of the above-mentioned considerations, it is interesting to note that the FPR-related research with regards to bias agonism did not prosper during considerably during the last decade (possible exceptions are [[8], [9], [10], [11]]. However, with new insights in receptor chemistry and fu

• br Conclusions Our in vitro and

  2021-12-16

  

  Conclusions Our in vitro and in vivo data collectively demonstrate that zifaxaban is effective in preventing thrombus formation via direct and specific inhibition of FXa in a dose-dependent manner. Furthermore, zifaxaban has a potency that is similar to that of rivaroxaban and shows a similar or

• In human cancers it has been identified that

  2021-12-16

  

  In human cancers, it has been identified that FOXC2-AS1 functions as an oncogenic RNA. For instance, in osteosarcoma, FOXC2-AS1 regulates the expression of FOXC2 at the transcription and post-transcription levels to promote doxorubicin resistance by facilitating ABCB1 expression (C.L. Zhang et al.,

16227 records 530/1082 page Previous Next First page 上5页 526527528529530 下5页 Last page